SCHEMBL21705018

SCHEMBL21705018

O=C(Cl)c1cccc(N(CC2CC2)C(=O)c2ccc(F)cc2)c1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 1/20 0.43
ACHE P22303 1/20 0.40
AGER Q15109 2/20 0.36
MTNR1A P48039 1/20 0.36
GPBAR1 Q8TDU6 1/20 0.36
HSD17B10 Q99714 1/20 0.35
LPAR1 Q92633 5/20 0.35
LPAR5 Q9H1C0 5/20 0.35
HDAC8 Q9BY41 1/20 0.35
HCRTR1 O43613 1/20 0.34
HCRTR2 O43614 1/20 0.34
MLYCD O95822 1/20 0.34
HSD11B1 P28845 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
PDK1 Q15118 1/20 0.33
DRD2 P14416 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
HTR2B P41595 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30222004 1.00 S1PR1 (0.43) S1PR1ACHEAGERMTNR1AGPBAR1
SCHEMBL21704816 0.92 S1PR1 (0.49) S1PR1AGERGPBAR1LPAR1LPAR5
SCHEMBL21693611 0.92 S1PR1 (0.39) S1PR1ACHEGPBAR1LPAR1LPAR5
SCHEMBL21705017 0.89 S1PR1 (0.41) S1PR1ACHEAGERMTNR1AHSD17B10
SCHEMBL30221925 0.89 S1PR1 (0.41) S1PR1ACHEAGERMTNR1AHSD17B10
SCHEMBL21701267 0.89 GPBAR1 (0.43) S1PR1GPBAR1HDAC8HCRTR1HCRTR2
SCHEMBL29857251 0.88 S1PR1 (0.41) S1PR1ACHEAGERMTNR1AHSD17B10
SCHEMBL30222070 0.88 NSD2 (0.41) S1PR1GPBAR1LPAR1LPAR5HDAC8
SCHEMBL21701240 0.88 NSD2 (0.41) S1PR1GPBAR1LPAR1LPAR5HDAC8
SCHEMBL29180257 0.85 CYP1A2 (0.42) S1PR1ACHELPAR1LPAR5HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119798108-A Preparation method of inner-ring profenofos and intermediate thereof in micro-channel 福州大学 2025-04-11 CN claimed
CN-116178198-A Preparation method of cyflufenapyr 南通泰禾化工股份有限公司 2023-05-30 CN claimed
CN-119798108-A Preparation method of inner-ring profenofos and intermediate thereof in micro-channel 福州大学 2025-04-11 CN disclosed
EP-3816150-B1 M-DIAMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF CAC SHANGHAI INT TRADING CO LTD (CN) 2024-07-24 EP disclosed
CN-116178198-A Preparation method of cyflufenapyr 南通泰禾化工股份有限公司 2023-05-30 CN disclosed
CN-115872889-A Method for preparing o-trifluoromethylaniline compound 沈阳中化农药化工研发有限公司 2023-03-31 CN disclosed
US-11540516-B2 M-diamide compound and preparation method therefor and use thereof CAC SHANGHAI INTERNATIONAL TRADING CO., LTD. (CN) 2023-01-03 US disclosed
US-11540516-B2 M-diamide compound and preparation method therefor and use thereof CAC SHANGHAI INTERNATIONAL TRADING CO., LTD. (CN) 2023-01-03 US disclosed
CN-113767907-B Pharmaceutical composition containing m-diamide compounds and application thereof 南通泰禾化工股份有限公司 2022-11-29 CN disclosed
CN-113767908-B Pharmaceutical composition containing m-diamide compound and application thereof 南通泰禾化工股份有限公司 2022-11-18 CN disclosed
CN-110810410-B Pharmaceutical composition containing m-diamide compound and application thereof 南通泰禾化工股份有限公司 2022-02-11 CN disclosed
US-20200178525-A1 M-DIAMIDE COMPOUND AND PREPARATION METHOD THEREOF AND USE THEREOF CAC SHANGHAI INTERNATIONAL TRADING CO., LTD. (CN) 2020-06-11 US disclosed
US-20200178525-A1 M-DIAMIDE COMPOUND AND PREPARATION METHOD THEREOF AND USE THEREOF CAC SHANGHAI INTERNATIONAL TRADING CO., LTD. (CN) 2020-06-11 US disclosed
CN-110810414-A Pharmaceutical composition containing m-diamide compound and application thereof 苏州佳辉化工有限公司 2020-02-21 CN disclosed
CN-110810413-A Pharmaceutical composition containing m-diamide compound and application thereof 上海泰禾国际贸易有限公司 2020-02-21 CN disclosed
CN-110810409-A Pharmaceutical composition containing m-diamide compound and application thereof 上海泰禾国际贸易有限公司 2020-02-21 CN disclosed
CN-110810410-A Pharmaceutical composition containing m-diamide compound and application thereof 上海泰禾国际贸易有限公司 2020-02-21 CN disclosed
CN-110810412-A Pharmaceutical composition containing m-diamide compound and application thereof 苏州佳辉化工有限公司 2020-02-21 CN disclosed
WO-2020030092-A1 PHARMACEUTICAL COMPOSITION CONTAINING M-DIAMIDE COMPOUND AND APPLICATION THEREOF 上海泰禾国际贸易有限公司 2020-02-13 WO disclosed
WO-2020030094-A1 PHARMACEUTICAL COMPOSITION COMPRISING META-DIAMIDE COMPOUND AND USE THEREOF 上海泰禾国际贸易有限公司 2020-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11540516-B2 M-diamide compound and preparation method therefor and use thereof DIMT1, DDT, MRM1 S1PR1 3653/4885ACHE 72/4885AGER 864/4885
US-20200178525-A1 M-DIAMIDE COMPOUND AND PREPARATION METHOD THEREOF AND USE THEREOF DDT, DIMT1, QDPR S1PR1 3752/4885ACHE 24/4885AGER 633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.